The Melbourne healthtech’s oversubscribed Series A, led by Airtree, funds a move into the UK and a pitch to coordinate a patient’s health data over a lifetime rather than a single appointment.
Most healthcare systems are built to wait. They are organised around the moment something goes wrong, the appointment booked because a symptom appeared, with the records, the specialists and the follow-up scattered across providers that rarely talk to one another.
Everlab, a Melbourne healthtech founded in 2023, has raised AU$65m to bet on the opposite premise: that the more valuable system is the one that notices the problem before the patient does.
The Series A, which the company says was oversubscribed, was led by Australia’s Airtree Ventures, with participation from Europe’s Plural and existing backers Left Lane Capital in the US and b2venture in Europe.
The 💜 of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!
Among the angel investors is the Australian Test cricket captain Pat Cummins. It is a substantial step up from the company’s US$10m seed round, raised less than a year earlier in July 2025.
What the round funds is a shift from a collection of services to a single platform. Everlab’s app pulls diagnostics, doctors, specialists, prescriptions and what it calls continuous AI care into one place, with the aim of giving a patient a longitudinal view of their health, the full record over time rather than a series of disconnected snapshots.
The company says it integrates with more than 1,850 health-provider locations, over 180 active clinicians and more than 30 wearable devices, and processes upwards of 200,000 health reports a month.
“The existing system is fragmented, handing patients between providers and hoping the information follows,” said Marc Hermann, Everlab’s co-founder and chief executive. “We built Everlab to hold the full picture, surface health blind spots and coordinate what needs to happen next.”
The framing is one we have seen recur across the sector, from Perplexity Health to the medical wearables now feeding clinical platforms: the value is moving from the device or the appointment to the layer that interprets and connects them.
The numbers Everlab attaches to its case are about engagement and detection. The company says it has completed more than 40,000 consultations for 20,000 patients, including corporate clients such as Boston Consulting Group, BHP and Bain & Company, and has processed more than 21 million biomarker results.
More than a quarter of members, it says, have had findings flagged that the existing system had not picked up, the figure the whole preventative pitch rests on.
For Carina Namih, a partner at Plural, that distinction is the investment thesis. “Every company that has tried to own the patient journey has ended up either selling doctor time by the minute or reselling lab tests with thin margins,” she said.
“Everlab is building the layer above both.” John Henderson of Airtree was blunter about the ambition, calling Everlab “a generational health business” already leading in Australia and positioned, in his view, to do the same internationally.
That international move starts with the United Kingdom, Everlab’s first market beyond Australia and its entry point into what the company describes as a $10 trillion global consumer-healthcare market. The funding, it says, will go towards strengthening its clinical and technology infrastructure and accelerating the rollout.
The harder test is the one the company has set itself: proving that prevention, the thing every health system says it wants and few are built to deliver, can be run at scale and still pay for itself.
Stephan is the sports journalist for the Maple Grove Report.
